The effects of bromocriptine and terguride on the estrogen-stimulated anterior pituitary gland of the fe male Wistar rat were investigated. Pituitary weight and serum prolactin (PRL) levels were reduced by treatment with bromocriptine or terguride. Immunohistological staining for proliferating cell nuclear antigen (PCNA) revealed that the PCNA labeling index of PRL-producing cells was significantly decreased by treatment with bromocriptine or terguride compared with untreated cells. The number of apoptotic cells analyzed by the terminal deoxynucleotidyl transferase-mediated deoxyuridinetriphos phate-biotin nick end labeling method was significantly increased in rats treated with bromocriptine or terguride. Suppression of cell proliferation and induction of apoptosis are important effects of bromocriptine and terguride in the treatment of prolactinomas and other hyperprolactinemias.
guride act to suppress cell proliferation and induce apoptosis,3,12) but the mechanisms of these effects are not known.
This study investigated the effects of bromocrip tine and terguride in the estrogen-stimulated rat an terior pituitary gland by analyzing the relationship between proliferative cell index, apoptotic cell in dex, and the drug administered.
Materials and Methods
Twenty-two female Wistar rats (Clea Japan, Inc., Tokyo), 4 weeks of age and weighing 125-150 g, were housed with free access to tap water and stan dard pellet food. Eighteen rats received subcutane ous estradiol dipropionate injections (2.5 mg/0.5 ml/ rat) weekly for 8 weeks. The other four rats received no estrogen treatment. Beginning 1 week after com pletion of estradiol injections, groups of six rats received bromocriptine (5 mg/kg) or terguride (1 mg/kg) orally once a day for 4 weeks. Six other rats which had received estrogen injections received no oral agents during this period. Serum specimens were collected from all rats 3 to 5 hours after the fi nal dose of bromocriptine or terguride, including rats receiving neither. Then all rats were killed un der anesthesia using pentobarbital sodium injec tions. The pituitary glands were removed and the wet weight of each gland was recorded. Tissues were fixed with 10% buffered formalin, embedded in paraffin, sectioned, and then stained with HE.
Immunohistological studies used two series of sec tions deparaffinized in xylene and rehydrated through a graded series of ethanol to phosphate buffered saline. Endogenous peroxidase activity was blocked by placement in 0.3% hydrogen peroxidase in methanol for 30 minutes. The series of sections stained for the proliferating cell nuclear antigen (PCNA) (anti-PCNA; DAXO, San Diego, Calif., U.S.A.) was placed in 0.01 M citrate buffer and heat ed three times for 3 minutes at 500 W in a micro wave oven (modified method according to Shi et a1.311). These sections were then saturated with 5% normal goat serum for 30 minutes and incubated with anti-PCNA antibody diluted 1:100 at 40C for 24 hours or with anti-rat prolactin (PRL) antibody (A539/R4H; UCB-Bioproducts, Sandown, N.H., U.S.A.) diluted 1:200 at room temperature for 1 hour. The antigen-antibody complex was visualized using the avidin-biotin-peroxidase complex (ABC) method. Meyer's hematoxylin was used as a nu clear counterstain.
Apoptotic cells were detected with an apoptosis kit (MIBSTAIN Apoptosis kit; MBL, Nagoya) based on the terminal deoxynucleotidyl transferase (TdT) mediated deoxyuridinetriphosphate (dUTP)-biotin nick end labeling (TUNEL) method. 15) The deparaffin ized sections were incubated with proteinase K at 37° C for 30 minutes and immersed in TdT buffer at room temperature for 10 minutes. After removal of this buffer, the sections were immersed in TdT solution (TdT buffer 90 µl, biotin-dUTP 5µl, TdT 5 pl) at 370C for 1 hour. This solution was then re moved and the sections were placed in TB buffer (300 mM sodium chloride, 30 mM sodium citrate) at room temperature for 15 minutes. The antigen antibody complex was visualized using the ABC method. Meyer's hematoxylin was used as a nu clear counterstain.
The PCNA labeling index and apoptotic cell index were calculated for representative sections. More than 2000 cell nuclei of the anterior pituitary glands were counted in several viable areas of the same sec tion. All comparisons between groups used analysis of variance tests. P values less than 0.05 were con sidered significant. All values are given as the mean ± SD.
Results PRL-producing tumors were induced in all estrogen stimulated rat anterior pituitary glands (Fig. 1) . No necrosis was seen. One estrogen-treated rat died af ter 7 weeks of estrogen stimulation because of mas sive growth of the prolactinoma. Table 1 shows the results of analysis of the pituitary glands and serum PRL measurement. Estrogen treatment significantly increased the weight (p < 0.01) and serum PRL level (p < 0.05) compared to the untreated rats. Adminis tration of bromocriptine significantly reduced the ef fect of estrogen on the weight of the pituitary gland (p < 0.05) and on the serum PRL level (p < 0.05). Similarly, terguride administration significantly reduced the effect on the pituitary gland (p < 0.01) and the serum PRL level (p < 0.05). The anterior pituitary glands of all estrogen-stimulated rats con tained PCNA-positive cells (Fig. 2) . Both bromocrip tine and terguride significantly reduced (p < 0.01) the PCNA labeling index (Table 1 ). The pituitary glands from rats which received bromocriptine or terguride contained apoptotic cells which showed condensed nuclear chromatin within the nuclear membrane and shrinkage of cells reflecting conden sation of the nucleus and cytoplasm (Fig. 3) . Both bromocriptine and terguride caused a significant increase (p < 0.05) in the apoptosis index (Table  1) . 
Discussion
Long-term estrogen stimulation is well-known to in duce pituitary neoplasms in rats.2,9,2o,38,39) Prolactino mas are induced over a period of 7 weeks by weekly 2.5 mg subcutaneous estradiol injections.20) In our study, estradiol dipropionate was used to induce prolactinomas from the lactotrophic cells of the an terior pituitary gland. Lactotrophic cell proliferation is the initial event in the development of PRL-secret ing neoplasms following estrogen stimulation.3) Es trogen decreases dopamine uptake in the lactotroph ic cell,") increases receptors for thyroid-stimulating hormone-releasing hormone,') and induces hyper prolactinemia. Table 1 Effects of bromocriptine and terguride on the pituitary glands and serum prolactin (PRL) level Dopamine agonists stimulate D2 receptors which cause the suppression of PRL secretion.") Adminis tration of a dopamine agonist induces marked cellu lar involution characterized by reduction of the cel lular, cytoplasmic, nuclear, and nucleolar sizes, an increase in the nuclear-cytoplasmic ratio, and a decrease in cytoplasmic volume densities of en doplasmic reticulum and Golgi complexes.") Ergot derivatives such as bromocriptine and terguride reduce serum PRL levels in humans as well as rats. 8,10,17,23,26,27,35,40) Part of the effect of estrogen on lac totrophic cells is mediated through inhibition of the actions of dopamine. 1,13,27) Bromocriptine and tergu ride bind with high affinity to dopamine receptors in the pituitary gland and significantly lower the serum PRL levels in lactating rats .27,31) The bioavailability of terguride (approximately 30%) is five-fold higher than that of bromocriptine (approximately 6%).24,32,37) The amounts of these agents administered in our study were chosen according to these bioavailability figures. Both bromocriptine and terguride caused significant decreases in serum PRL levels and pitui rats. This leads us to believe that the rat was not completely resistant to bromocriptine, but may have required a larger dose. One of 14 bromocriptine-resistant patients was given increasing doses of bromocrip tine over a 9-day period.34) While her serum bromocriptine levels rose progressively, serum high PRL levels remained unchanged. The basis of the resistance to dopamine agonist therapy is still un clear.
PCNA is an auxiliary protein of deoxyribonucleic acid (DNA) polymerase-b, which is located in the nucleus and is expressed in each phase of the cell cycle except for G0.5.30) Monoclonal anti-PCNA an tibody can be used to detect PCNA paraffin-embed ded tissue sections.14) Cellular proliferation in the an terior pituitary gland in the female rat fluctuates drastically with the highest activity seen during es trus and the lowest during diestrus.28) The number of PCNA-positive cells increases after estrogen stimula tion.') Bromocriptine suppresses PRL secretion and DNA synthesis in lactotrophic cells via an intracellu lar negative feedback mechanism.",") In our study, the PCNA labeling indices of the groups receiving bromocriptine and terguride were approximately one third that of the group receiving no drug. This result suggests that terguride as well as bromocrip tine has suppressive effects. Short-term bromocrip tine therapy (4 to 6 weeks) causes histological changes including clumping of nuclear chromatin and marked reduction in cytoplasmic volume.",") No necrosis occurs in connection with these changes.") However, necrotic changes may appear in prolactinomas after long-term bromocriptine ad ministration (14 to 36 weeks).16) In our study of short term bromocriptine and terguride treatment, no necrosis occurred, and cell loss resulted from apop tosis. Therefore, bromocriptine and terguride have cytocidal effects on prolactinoma even after short term administration.
The TUNEL method is useful for detecting apop totic cells in situ,") and apoptotic cells in rapidly renewing normal tissues can be located by a modifi cation of this method.") In our study, the TUNEL method detected apoptotic cells in prolactinomas of estrogen-stimulated rats. The number of positively stained cells (apoptotic cell index) in the rats treated with bromocriptine or terguride was nearly double that in the rats given no drug. The apoptotic cell in dex in estrogen-treated rats given bromocriptine was previously found to be nearly twice that seen in rats receiving no dopaminergic drug.") However, apoptotic cells were counted in sections stained with HE, raising questions of false positives or nega tives. Our TUNEL staining method resulted in clear 
